Pharmaceutical - Antibiotics and Infectious diseases, Financial

Filter

Popular Filters

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints

04-08-2014

USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

15-07-2014

New Zealand Pharmaceutical Management Agency PHARMAC has awarded a tender to Netherlands-headquartered…

Antibiotics and Infectious diseasesFinancialHealthcareNew ZealandNorginePharmaceuticalXifaxan

Joint purchasing of vaccines and medicines becomes a reality in the EU

Joint purchasing of vaccines and medicines becomes a reality in the EU

10-04-2014

The European Commission today approved a Joint Procurement Agreement, which will enable all European…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceuticalVaccines

MRCF invests in Australian antibiotics start-up Auspherix

03-12-2013

Auspherix Pty, an early stage anti-infectives company developing novel antibiotics to treat resistant…

Antibiotics and Infectious diseasesAsia-PacificAuspherixAustraliaFinancialPharmaceuticalResearch

EU steps up its fight against drug-resistant bacteria

15-11-2013

A survey published by the European Commission today (November 15) reveals a decrease in antibiotic use…

Antibiotics and Infectious diseasesEuropeFinancialPharmaceuticalResearch

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds

20-06-2013

Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Rising drug resistance driving early-line use of powerful antibiotics, according to surveyed EU5 physicians

13-06-2013

More than half of physicians surveyed by health care advisory firm, Decision Resources from the EU5 (France,…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceutical

GlaxoSmithKline gets $200 million BARDA award to develop new antibiotics

22-05-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and the Biomedical Advanced Research and Development Authority…

Antibiotics and Infectious diseasesFinancialGlaxoSmithKlinePharmaceuticalResearch

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone

02-05-2013

US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

New European anti-infectives company, Allecra Therapeutics, created

18-04-2013

The creation of Allecra Therapeutics, a new company joining the established European BioValley Life Sciences…

Allecra TherapeuticsAntibiotics and Infectious diseasesFinancialOrchid Chemicals & PharmaceuticalsPharmaceuticalResearch

New executive director of the Global Fund outlines ambitious agenda

21-01-2013

Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis…

Anti-viralsAntibiotics and Infectious diseasesFinancialManagementPharmaceuticalTropical diseases

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK

20-12-2012

NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

Pfizer agrees $55 million settlement for off-label promotion of Protonix by Wyeth; strikes deal over Zyvox and Lyrica

13-12-2012

USA-based Pfizer (NYSE: PFE), the world's largest drugmaker by sales, has agreed to pay $55 million plus…

Antibiotics and Infectious diseasesFinancialGastro-intestinalsLegalLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticalProtonixWyethZyvox

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab

06-11-2012

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

Cubist unveils five-year strategic goals; enters antibiotics collaboration

12-06-2012

USA-based Cubist Pharmaceuticals (Nasdaq: CBST) has announced its five-year strategic aspirations - Building…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsEnteregFinancialFundacion MEDINAPharmaceuticalResearch

Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe

11-06-2012

USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropeFinancialLicensingOptimer PharmaceuticalsPharmaceutical

Parexel

Parexel

Back to top